Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Elena
E
Salvatore
Vincenzo Brescia
VB
Morra
Giuseppe
G
Orefice
Gary
G
Birnbaum
Bruce
B
Cree
Irfan
I
Altafullah
Anthony
A
Reder
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000069059:Atorvastatin; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*
D000276:Adjuvants, Immunologic; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D016899:Interferon-beta; D000069059:Atorvastatin; D000068556:Interferon beta-1a